**Core Concept**
Amyloid protein folding defects are a hallmark of various neurodegenerative disorders, including Alzheimer's disease, where misfolded amyloid-β peptides aggregate to form insoluble fibrils. This process disrupts normal cellular function, leading to neuronal damage and death. The pathophysiology of amyloid protein folding defects is closely linked to the protein's secondary structure and aggregation mechanisms.

**Why the Correct Answer is Right**
The amyloid-β protein is a 39-43 amino acid peptide derived from the amyloid precursor protein (APP). In Alzheimer's disease, the enzyme beta-secretase cleaves APP, resulting in the release of amyloid-β. The amyloid-β peptide then undergoes further processing by gamma-secretase, leading to the formation of the amyloid-β 40 or 42 peptides. These peptides misfold and aggregate, forming insoluble fibrils that are toxic to neurons. The amyloid-β 42 peptide is particularly prone to aggregation due to its high β-sheet content and hydrophobicity.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not relevant to the question.
* **Option B:** This option is not a known defect in amyloid protein folding.
* **Option C:** This option is not directly related to amyloid protein folding defects.

**Clinical Pearl / High-Yield Fact**
The amyloid-β 42 peptide is a key player in the pathogenesis of Alzheimer's disease, and its aggregation is thought to be the primary driver of neuronal damage and death.

**Correct Answer: D. Familial Alzheimer's disease (FAD) is often associated with mutations in the APP gene, leading to defects in amyloid protein folding.**